A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state

Molecular Pharmacology

Volumn 74, Issue 3, 2008, Pages 641-653

  Mathiasen, Lisa ^a   Dupont, Daniel M ^a   Christensen, Anni ^a   Blouse, Grant E ^a   Jensen, Jan K ^a   Gils, Ann ^b   Declerck, Paul J ^b   Wind, Troels ^a   Andreasen, Peter A ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COAT PROTEIN; CYSTEINE; HEPARIN; HYBRID PROTEIN; LIGAND; MONOCLONAL ANTIBODY; PAIONIN 4 PROTEIN; PEPTIDE LIBRARY; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BACTERIOPHAGE; BINDING SITE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG TARGETING; ESCHERICHIA COLI; HUMAN; LATENT INHIBITION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; BINDING, COMPETITIVE; EPITOPES; HEPARIN; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PEPTIDES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION MAPPING; RECOMBINANT FUSION PROTEINS; SURFACE PLASMON RESONANCE; THERMODYNAMICS;

EID: 50449087284     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.046417     Document Type: Article

References (60)

1. Andersen LM, Wind T, Hansen HD, and Andreasen PA (2008) A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: Changing species specificity by substitution of a single residue. Biochem J 412:447-457.
2. Andreasen PA (2007) PAI-1 - a potential therapeutic target in cancer. Curr Drug Targets 8:1030-1041.
3. Andreasen PA, Egelund R, Jensen S, and Rodenburg KW (1999) Solvent effects on activity and conformation of plasminogen activator inhibitor-1. Thromb Haemost 81:407-414.
4. Andreasen PA, Egelund R, and Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57:25-40.
5. Andreasen PA, Kjøller L, Christensen L, and Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72:1-22.
6. Berkenpas MB, Lawrence DA, and Ginsburg D (1995) Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 14:2969-2977.
7. Björquist P, Ehnebom J, Inghardt T, Hansson L, Lindberg M, Linschoten M, Strömqvist M, and Deinum J (1998) Identification of the binding site for a lowmolecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis. Biochemistry 37:1227-1234.
8. Blouse GE, Perron MJ, Kvassman JO, Yunus S, Thompson JH, Betts RL, Lutter LC, and Shore JD (2003) Mutation of the highly conserved tryptophan in the serpin breach region alters the inhibitory mechanism of plasminogen activator inhibitor-1. Biochemistry 42:12260-12272.
9. Bødker JS, Wind T, Jensen JK, Hansen M, Pedersen KE, and Andreasen PA (2003) Mapping of the epitope of a monoclonal antibody protecting plasminogen activator inhibitor-1 against inactivating agents. Eur J Biochem 270:1672-1679.
10. Bryans J, Charlton P, Chicarelli-Robinson I, Collins M, Faint R, Latham C, Shaw I, and Trew S (1996) Inhibition of plasminogen activator inhibitor-1 activity by two diketopiperazines, XR330 and XR334 produced by Streptomyces sp. J Antibiot (Tokyo) 49:1014-1021.
11. Charlton P, Faint R, Barnes C, Bent F, Folkes A, Templeton D, Mackie I, Machin S, and Bevan P (1997) XR5118, a novel modulator of plasminogen activator inhibitor-1 (PAI-1), increases endogenous tPA activity in the rat. Fibrinolysis Proteolysis 11:51-56.
12. Charlton PA, Faint RW, Bent F, Bryans J, Chicarelli-Robinson I, Mackie I, Machin S, and Bevan P (1996) Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb Haemost 75:808-815.
13. Chikanishi T, Shinohara C, Kikuchi T, Endo A, and Hasumi K (1999) Inhibition of plasminogen activator inhibitor-1 by 11-keto-9(E),12(E)-octadecadienoic acid, a novel fatty acid produced by Trichoderma sp. J Antibiot (Tokyo) 52:797-802.
14. Crandall DL, Elokdah H, Di L, Hennan JK, Gorlatova NV, and Lawrence DA (2004) Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy. J Thromb Haemost 2:1422-1428.
15. Declerck PJ, Verstreken M, and Collen D (1995) Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 74:1305-1309.
16. De Nanteuil G, Lila-Ambroise C, Rupin A, Vallez MO, and Verbeuren TJ (2003) New fibrinolytic agents: benzothiophene derivatives as inhibitors of the t-PA-PAI-1 complex formation. Bioorg Med Chem Lett 13:1705-1708.
17. Dupont DM, Blouse GE, Hansen M, Mathiasen L, Kjelgaard S, Jensen JK, Christensen A, Gils A, Declerck PJ, Andreasen PA, et al. (2006) Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C. J Biol Chem 281:36071-36081.
18. Durand MK, Bødker JS, Christensen A, Dupont DM, Hansen M, Jensen JK, Kjelgaard S, Mathiasen L, Pedersen KE, Skeldal S, et al. (2004) Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 91:438-449.
19. Egelund R, Einholm AP, Pedersen KE, Nielsen RW, Christensen A, Deinum J, and Andreasen PA (2001a) A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-neutralizing ligands. ligand-induced serpin polymerization. J Biol Chem 276:13077-13086.
20. Egelund R, Petersen TE, and Andreasen PA (2001b) A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism. Eur J Biochem 268:673-685.
21. Ehnebom J, Björquist P, Anderson J-O, Johansson T, and Deinum J (1997) Detergent Tween 80 modifies the specific activity of PAI-1. Fibrinolysis Proteolysis 11:165-170.
22. Ehrlich HJ, Gebbink RK, Keijer J, and Pannekoek H (1992) Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin. J Biol Chem 267:11606-11611.
23. Einholm AP, Pedersen KE, Wind T, Kulig P, Overgaard MT, Jensen JK, Bødker JS, Christensen A, Charlton P, and Andreasen PA (2003) Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1. Biochem J 373:723-732.
24. Eitzman DT, Fay WP, Lawrence DA, Francis-Chmura AM, Shore JD, Olson ST, and Ginsburg D (1995) Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 95:2416-2420.
25. Folkes A, Roe MB, Sohal S, Golec J, Faint R, Brooks T, and Charlton P (2001) Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1. Bioorg Med Chem Lett 11:2589-2592.
26. Friederich PW, Levi M, Biemond BJ, Charlton P, Templeton D, van Zonneveld AJ, Bevan P, Pannekoek H, and ten Cate JW (1997) Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces post-thrombolysis thrombus growth in rabbits. Circulation 96:916-921.
27. Gårdsvoll H, van Zonneveld AJ, Holm A, Eldering E, van Meijer M, Danø K, and Pannekoek H (1998) Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI-1) using random peptide phage-display libraries. FEBS Lett 431:170-174.
28. Gils A and Declerck PJ (1998) Modulation of plasminogen activator inhibitor 1 by Triton X-100- identification of two consecutive conformational transitions. Thromb Haemost 80:286-291.
29. Gils A and Declerck PJ (2004) The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost 91:425-437.
30. Gils A, Knockaert I, Brouwers E, and Declerck PJ (2000) Glycosylation dependent conformational transitions in plasminogen activator inhibitor-1: evidence for the presence of two active conformations. Fibrinolysis Proteolysis 14:58-64.
31. Gils A, Pedersen KE, Skottrup P, Christensen A, Naessens D, Deinum J, Enghild JJ, Declerck PJ, and Andreasen PA (2003) Biochemical importance of glycosylation of plasminogen activator inhibitor-1. Thromb Haemost 90:206-217.
32. Gils A, Stassen JM, Nar H, Kley JT, Wienen W, Ries UJ, and Declerck PJ (2002) Characterization and comparative evaluation of a novel PAI-1 inhibitor. Thromb Haemost 88:137-143.
33. Gorlatova NV, Cale JM, Elokdah H, Li D, Fan K, Warnock M, Crandall DL, and Lawrence DA (2007) Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem 282:9288-9296.
34. Gorlatova NV, Elokdah H, Fan K, Crandall DL, and Lawrence DA (2003) Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function. J Biol Chem 278:16329-16335.
35. Hansen M, Wind T, Blouse GE, Christensen A, Petersen HH, Kjelgaard S, Mathiasen L, Holtet TL, and Andreasen PA (2005) A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition. J Biol Chem 280:38424-38437.
36. Huntington JA (2006) Shape-shifting serpins-advantages of a mobile mechanism. Trends Biochem Sci 31:427-435.
37. Jensen JK, Malmendal A, Schiøtt B, Skeldal S, Pedersen KE, Celik L, Nielsen NC, Andreasen PA, and Wind T (2006) Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library. Biochem J 399:387-396.
38. Koivunen E, Wang B, and Ruoslahti E (1994) Isolation of a highly specific ligand for the α5β1 integrin from a phage display library. J Cell Biol 124:373-380.
39. Kvassman JO and Shore JD (1995) Fibrinolysis:215-221.
40. Munch M, Heegaard C, Jensen PH, and Andreasen PA (1991) Type-1 inhibitor of plasminogen activators. Distinction between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies. FEBS Lett 295:102-106.
41. Munch M, Heegaard CW, and Andreasen PA (1993) Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim Biophys Acta 1202:29-37.
42. Naessens D, Gils A, Compernolle G, and Declerck PJ (2003) Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition. Thromb Haemost 90:52-58.
43. Neve J, Leone PA, Carroll AR, Moni RW, Paczkowski NJ, Pierens G, Björquist P, Deinum J, Ehnebom J, Inghardt T, et al. (1999) Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens. J Nat Prod 62:324-326.
44. Nielsen LS, Andreasen PA, Grøndahl-Hansen J, Huang JY, Kristensen P, and Danø K (1986) Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells-inhibitor neutralization and one-step affinity purification. Thromb Haemost 55:206-212.
45. Offersen BV, Nielsen BS, Høyer-Hansen G, Rank F, Hamilton-Dutoit S, Overgaard J, and Andreasen PA (2003) The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol 163:1887-1899.
46. Pedersen KE, Einholm AP, Christensen A, Schack L, Wind T, Kenney JM, and Andreasen PA (2003) Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands. Biochem J 372:747-755.
47. Schulze AJ, Baumann U, Knof S, Jaeger E, Huber R, and Laurell CB (1990) Structural transition of alpha 1-antitrypsin by a peptide sequentially similar to beta-strand s4A. Eur J Biochem 194:51-56.
48. Scott JK and Smith GP (1990) Searching for peptide ligands with an epitope library. Science 249:386-390.
49. Shore JD, Day DE, Francis-Chmura AM, Verhamme I, Kvassman J, Lawrence DA, and Ginsburg D (1995) A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J Biol Chem 270:5395-5398.
50. Stoppelli MP, Andersen LM, Votta G, and Andreasen PA (2008). Engineered antagonists of uPA and PAI-1. Springer, New York, in press.
51. Stout TJ, Graham H, Buckley DI, and Matthews DJ (2000) Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry 39:8460-8469.
52. Sumbayev VV, Bonefeld-Jørgensen EC, Wind T, and Andreasen PA (2005) A novel pesticide-induced conformational state of the oestrogen receptor ligand-binding domain, detected by conformation-specific peptide binding. FEBS Lett 579:541-548.
53. Urano T, Strandberg L, Johansson LB, and Ny T (1992) A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 209:985-992.
54. Vaughan DE (1998) Plasminogen activator inhibitor-1: a common denominator in cardiovascular disease. J Investig Med 46:370-376.
55. Verhamme I, Kvassman JO, Day D, Debrock S, Vleugels N, Declerck PJ, and Shore JD (1999) Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding. J Biol Chem 274:17511-17517.
56. Wang S, Golec J, Miller W, Milutinovic S, Folkes A, Williams S, Brooks T, Hardman K, Charlton P, Wren S, et al. (2002) Novel inhibitors of plasminogen activator inhibitor-1: development of new templates from diketopiperazines. Bioorg Med Chem Lett 12:2367-2370.
57. Wind T, Hansen M, Jensen JK, and Andreasen PA (2002) The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1. Roles of the reactive centre loop, the shutter region, the flexible joint-region and the small serpin fragment. Biol Chem 383:21-36.
58. Wind T, Jensen JK, Dupont DM, Kulig P, and Andreasen PA (2003) Mutational analysis of plasminogen activator inhibitor-1. Eur J Biochem 270:1680-1688.
59. Wind T, Jensen MA, and Andreasen PA (2001) Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1. Implications for antibody-mediated PAI-1-neutralization and vitronectin-binding. Eur J Biochem 268:1095-1106.
60. Xue Y, Björquist P, Inghardt T, Linschoten M, Musil D, Sjölin L, and Deinum J (1998) Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Structure 6:627-636.